Ethinylestradiol/Chlormadinone Acetate

被引:0
|
作者
Monique P. Curran
Antona J. Wagstaff
机构
[1] Adis International Limited,
来源
Drugs | 2004年 / 64卷
关键词
Luteinising Hormone; Oral Contraceptive; Acne; Combine Oral Contraceptive; Breakthrough Bleeding;
D O I
暂无
中图分类号
学科分类号
摘要
▴ Ethinylestradiol/chlormadinone acetate 0.03/2mg (EE/CMA) is a combined monophasic contraceptive pill with antiandrogenic properties.▴ In a large, noncomparative, multicentre trial (≤24 cycles of treatment per woman) and two (6- and 12-cycle) postmarketing surveillance studies, EE/ CMA was effective in preventing pregnancy.▴ EE/CMA was significantly more effective than EE/ levonorgestrel 0.03/0.15 mg/day in treating women with mild-to-moderate papulopustular acne of the face and related disorders in a randomised, single-blind, multicentre trial.▴ EE/CMA was well tolerated in clinical trials and the postmarketing surveillance studies. Adverse events were those commonly reported with oral contraceptives. As expected, the most common menstrual disturbances were breakthrough bleeding, spotting and amenorrhoea.
引用
收藏
页码:751 / 760
页数:9
相关论文
共 50 条
  • [1] Ethinylestradiol/chlormadinone acetate
    Kuhl, H
    DRUGS, 2004, 64 (07) : 762 - 762
  • [2] Ethinylestradiol/Chlormadinone Acetate Dermatological Benefits
    Guerra-Tapia, Aurora
    Sancho Perez, Blanca
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2011, 12 : 3 - 11
  • [3] Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders
    Mercedes Gómez Vázquez
    Ramón Navarra Amayuelas
    Marta Lamarca
    Laura Baquedano
    Sebastián Romero Ruiz
    Eduardo Vilar-Checa
    Maria D. Iniesta
    American Journal of Clinical Dermatology, 2011, 12 : 13 - 19
  • [4] Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders
    Gomez Vazquez, Mercedes
    Navarra Amayuelas, Ramon
    Lamarca, Marta
    Baquedano, Laura
    Romero Ruiz, Sebastian
    Vilar-Checa, Eduardo
    Iniesta, Maria D.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2011, 12 : 13 - 19
  • [6] Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate
    Terlinden, Rolf
    Uragg, Heinz
    Goehler, Karin
    Kneip, Christa
    CONTRACEPTION, 2006, 74 (03) : 239 - 244
  • [7] Ethinylestradiol/Chlormadinone AcetateDermatological Benefits
    Aurora Guerra-Tapia
    Blanca Sancho Pérez
    American Journal of Clinical Dermatology, 2011, 12 : 3 - 11
  • [8] Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
    Ferrari, Serena
    Cannoletta, Marianna
    Generali, Matteo
    Cazzato, Lucia
    Cagnacci, Angelo
    OPEN ACCESS JOURNAL OF CONTRACEPTION, 2010, 1 : 93 - 101
  • [9] Bioequivalence Study of Generic Tablet Formulations Containing Ethinylestradiol and Chlormadinone Acetate in Healthy Female Volunteers
    Bonn, Michael
    Eydeler, Urte
    Barkworth, Martin
    Rovati, Lucio C.
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2009, 59 (12): : 651 - 658
  • [10] Ethinylestradiol/Chlormadinone AcetateA Viewpoint by Ulrich Winkler
    Ulrich Winkler
    Drugs, 2004, 64 (7) : 761 - 761